Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

<br><strong>Background<br></strong> Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2). However, recent trial data...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Hinton, W, Feher, MD, Munro, N, Joy, M, de Lusignan, S
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	BioMed Central 2021

Antzeko izenburuak

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
nork: William Hinton, et al.
Argitaratua: (2021-06-01)

Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
nork: Hinton, W, et al.
Argitaratua: (2020)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
nork: Hinton, W, et al.
Argitaratua: (2020)

How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
nork: Hinton, W, et al.
Argitaratua: (2019)

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
nork: Shah, S, et al.
Argitaratua: (2018)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
nork: McGovern, A, et al.
Argitaratua: (2017)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
nork: McGovern, A, et al.
Argitaratua: (2017)

Sodium glucose co-transporter 2 inhibitors in heart failure therapy
nork: Yüksel Çavuşoğlu, et al.
Argitaratua: (2020-04-01)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)
nork: Michael Feher, et al.
Argitaratua: (2022-07-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
nork: E. V. Kovalenko, et al.
Argitaratua: (2021-02-01)

Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
nork: Yixuan Fang, et al.
Argitaratua: (2024-06-01)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
nork: Bo Liang, et al.
Argitaratua: (2022-05-01)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
nork: Qingchun Zeng, et al.
Argitaratua: (2021-02-01)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
nork: Gianmarco Angelini, et al.
Argitaratua: (2021-08-01)

Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction
nork: Dimitrios Patoulias, et al.
Argitaratua: (2024-07-01)

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
nork: Jiangjun Wei, et al.
Argitaratua: (2023-04-01)

A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population
nork: Forbes, AK, et al.
Argitaratua: (2024)

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
nork: Giuseppe Rosano, et al.
Argitaratua: (2020-11-01)

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
nork: Gassan Moady, et al.
Argitaratua: (2023-05-01)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
nork: Muhammad Shariq Usman, et al.
Argitaratua: (2022-04-01)

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
nork: Forbes, AK, et al.
Argitaratua: (2024)

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature
nork: Asfandyar Khattak, et al.
Argitaratua: (2024-04-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
nork: Riber Fabián Donoso Noroña, et al.
Argitaratua: (2024-09-01)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
nork: Shingo Kato, et al.
Argitaratua: (2023-04-01)

Individual Approach to Prescribing Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Hypertrophic Cardiomyopathy
nork: Vira Y. Tseluyko, et al.
Argitaratua: (2024-03-01)

Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
nork: Ivana Jurin, et al.
Argitaratua: (2024-11-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
nork: M. M. Batyushin
Argitaratua: (2021-04-01)

Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art
nork: Yilmar Alexader Meza-González, et al.
Argitaratua: (2023-02-01)

Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia
nork: Wen‐Jing Tang, et al.
Argitaratua: (2023-06-01)

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
nork: João Pedro Ferreira, et al.
Argitaratua: (2022-12-01)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
nork: Xizi Shen, et al.
Argitaratua: (2022-08-01)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
nork: Bo Liang, et al.
Argitaratua: (2022-06-01)

The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys
nork: Eirini Lioudaki, et al.
Argitaratua: (2022-03-01)

Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
nork: Yi‐Fang Weng, et al.
Argitaratua: (2023-04-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
nork: Muhammad Shahzeb Khan, et al.
Argitaratua: (2019-11-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
nork: Nicia I. Profili, et al.
Argitaratua: (2024-10-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
nork: Yang Cao, et al.
Argitaratua: (2022-06-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
nork: Yu. S. Ignatova, et al.
Argitaratua: (2024-02-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
nork: Shingo Kato, et al.
Argitaratua: (2022-10-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
nork: Juexing Li, et al.
Argitaratua: (2022-09-01)